# PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

> **NCT07025876** · EARLY_PHASE1 · COMPLETED · sponsor: **Jiangsu Province Centers for Disease Control and Prevention** · enrollment: 240 (actual)

## Conditions studied

- Streptococcus Pneumoniae Pneumonia

## Interventions

- **BIOLOGICAL:** low dose PCV24
- **BIOLOGICAL:** high dose PCV24
- **BIOLOGICAL:** PPV23
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07025876
- **Lead sponsor:** Jiangsu Province Centers for Disease Control and Prevention
- **Sponsor class:** NETWORK
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-18
- **Primary completion:** 2024-06-15
- **Final completion:** 2024-07-30
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07025876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07025876, "PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07025876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*